Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
AG-CR1-3618 Highly potent and selective competitive inhibitor of dipeptidyl-peptidase 4 (DPP4
Comments: Subcutaneous semaglutide 1 mg / week: 13 % improvement in walking distance vs placebo (med 26.4 m / avg 39.9 m) Improved quality of life (VascuQoL-6 and SF-36 questionnaires) Fewer rescue treatments vs placebo Improvement in ankle-brachial index (ABI) Modest weight loss of 4.1 kg with Semaglutide vs placebo Key benefits: Rapid benefit (from week 26) maintained over time (up to week 57) Improved performance on inclined treadmill Increased ABI, supporting a direct vascular benefit (anti-inflammatory action) Potential additional benefits: weight loss, cardiometabolic effects, renal benefits, major cardiovascular event reduction, heart failure benefits Limitations: Difficulty translating treadmill improvement to daily life activities Benefits may vary based on disease severity, functional demands, and patient expectations Study limited to diabetic patients Short-term evaluation of adverse major events Modest but statistically significant improvement in ABI warrants further mechanistic studies on PAD Other considerations: Weight loss and gastrointestinal effects may have revealed randomization, but unlikely to affect objective measures (walking distance or ABI) Other available medications: Pentoxifylline : Few benefits compared to placebo Cilostazol : Similar clinical improvement to Semaglutide Both increase walking distance without impact on cardiovascular health Get the latest clinical cases and breaking news delivered straight to your inbox!
[1] [7] When degradation occurs, the medication's ability to bind effectively to GIP and GLP-1 receptors diminishes, potentially reducing its glucose-lowering and weight management effects
Long COVID is a continuous issue, and a lot of elderly people are suffering from this, said Professor Chen
Low blood pressure (hypotension) is also rare occurring in fewer than 1% of patients and is typically related to dehydration caused by gastrointestinal side effects such as nausea, vomiting, or diarrhea
